Dr. Evan Y. Yu
Medical Oncology (Medical Oncology Physician)
Ambulatory Clinic, 825 Eastlake Avenue East
Seattle, WA 98109
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 75
Licensed in Washington since 2004, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Washington School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
WA license MD00044089 (first issued 2004; active) -
Internal Medicine Physician
WA license MD00044089 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 75
- Services billed
- 217
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 166 | 86 |
| Established patient office or other outpatient visit, 30-39 minutes | 60 | 41 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 37 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Seattle, WA | 32 |
| Abiraterone Acetate | 30 |
| Nubeqa (darolutamide) | 13 |
| Bicalutamide | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 56 payments worth $51,434 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $23,920 |
|---|---|
| Merck Sharp & Dohme LLC | $13,252 |
| Astellas Pharma Global Development | $3,610 |
| Janssen Biotech, Inc. | $2,927 |
| Novartis Pharmaceuticals Corporation | $2,519 |
| Janssen Scientific Affairs, LLC | $1,846 |
| Tolmar, Inc. | $1,500 |
| Samsung Bioepis Co., LTD. | $1,040 |
| Consulting Fee | $33,082 |
|---|---|
| Travel and Lodging | $17,186 |
| Food and Beverage | $1,167 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Consulting Fee Xofigo · Oncology | $9,373 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Vienna, Austria · in-kind | $9,080 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Consulting Fee | $4,480 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $4,403 |
| Astellas Pharma Global Development Jun 14, 2025 | Consulting Fee Xtandi · Oncology | $3,500 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Consulting Fee Nubeqa · Oncology | $2,524 |
| Novartis Pharmaceuticals Corporation Nov 10, 2025 | Consulting Fee PLUVICTO · Oncology | $2,450 |
| Merck Sharp & Dohme LLC Jun 2, 2025 | Consulting Fee | $2,240 |
| Janssen Scientific Affairs, LLC Jun 12, 2025 | Consulting Fee ERLEADA · Oncology | $1,635 |
| Tolmar, Inc. Feb 14, 2025 | Consulting Fee | $1,500 |
All 34 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Vienna, Austria · in-kind | $9,080 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 16, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Vienna, Austria · in-kind | $189 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 13, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Vienna, Austria · in-kind | $189 |
| Novartis Pharmaceuticals Corporation Nov 10, 2025 | Consulting Fee PLUVICTO · Oncology | $2,450 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Consulting Fee | $4,480 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Travel and Lodging travel to Berlin, Germany | $150 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $4,403 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $150 |
| Merck Sharp & Dohme LLC Oct 15, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $260 |
| Merck Sharp & Dohme LLC Oct 15, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $237 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Consulting Fee Nubeqa · Oncology | $2,524 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Rosemont, IL · in-kind | $130 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Rosemont, IL · in-kind | $26.88 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Consulting Fee Xofigo · Oncology | $9,373 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $449 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 25, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $238 |
| Samsung Bioepis Co., LTD. Jul 24, 2025 | Consulting Fee E303 · Medical Oncology | $1,040 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 24, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $238 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 24, 2025 | Travel and Lodging Xofigo · Oncology · travel to Rosemont, IL · in-kind | $215 |
| Astellas Pharma Global Development Jun 14, 2025 | Consulting Fee Xtandi · Oncology | $3,500 |
| Astellas Pharma Global Development Jun 14, 2025 | Travel and Lodging Xtandi · Oncology · travel to Seattle, WA | $110 |
| Janssen Biotech, Inc. Jun 13, 2025 | Consulting Fee ERLEADA · Oncology | $1,410 |
| Janssen Scientific Affairs, LLC Jun 12, 2025 | Consulting Fee ERLEADA · Oncology | $1,635 |
| Janssen Scientific Affairs, LLC Jun 12, 2025 | Travel and Lodging ERLEADA · Oncology · travel to CHICAGO, IL | $93.10 |
| Merck Sharp & Dohme LLC Jun 2, 2025 | Consulting Fee | $2,240 |
| Bayer HealthCare Pharmaceuticals Inc. May 22, 2025 | Consulting Fee | $700 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX Company’s descriptionProvided as part of a clinical research engagement. | $95.84 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $456 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $205 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $156 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $113 |
| AstraZeneca UK Limited Apr 1, 2025 | Consulting Fee Truqap · Oncology | $820 |
| Janssen Biotech, Inc. Mar 28, 2025 | Consulting Fee ERLEADA · Oncology | $1,410 |
| Tolmar, Inc. Feb 14, 2025 | Consulting Fee | $1,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 6 companies. The companies reported $783,648 in research payments for these studies, mostly to the institutions running them.
- Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365
Merck Sharp & Dohme LLC - An openlabel randomized controlled phase 3 study of disitamab vedotin in combination with pembrolizumab versus chemotherapy in subjects with previously untreated locally advanced or metastatic urothelial carcinoma tha…
Pfizer Inc. - A phase 2 multicohort openlabel multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48ADC alone or in combination with pembrolizumab in subjects with locallyadvanced unresectable or me…
Seagen Inc. - A phase 2 multi cohort open label multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48 adc in subjects with HER2 expressing locally advanced unresectable or metastatic urothelial car…
Seagen Inc. - Prostate specific membrane antigen (psma) or fluciclovine (facbc) pet/ct site-directed therapy of oligometastatic prostate cancer (p-flu-blastpc)
Progenics Pharmaceuticals, Inc. - INVFE
Progenics Pharmaceuticals, Inc. - MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With …
Merck Sharp & Dohme LLC - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01
Merck Sharp & Dohme LLC - A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability and Pharmacokinetic Study of TAS3681 in Patients With Metastatic Castration Resistant Prostate Cancer
Taiho Oncology, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.